Demographic and clinical determinants of multi drug resistant tuberculosis among HIV infected patients in Tanzania

John, Mgogwe and Hadija, Semvua and Oliva, Massay and Balthazar, Nyombi and Jaffu, Chilongola (2020) Demographic and clinical determinants of multi drug resistant tuberculosis among HIV infected patients in Tanzania. International Journal of Medicine and Medical Sciences, 12 (2). pp. 23-32. ISSN 2006-9723

[thumbnail of B51E14164811] Text
B51E14164811 - Published Version

Download (554kB)

Abstract

Multi Drug Resistant Tuberculosis (MDR-TB) is a public health challenge, which itself remains a global public health problem. Its impact is worsened by co-infection with Human immunodeficiency virus (HIV). In order to institute successful TB control strategies, factors for development of MDR-TB must be understood. This study aimed to identify and describe clinical and demographic determinants for development of MDR-TB among TB patients. This was a cross sectional, hospital-based study conducted between April 2017 and December 2019 involving 428 presumptive MDR-TB patients. Specimens were subjected to GeneXpert MTB/RIF assay, microscopy and Line probe assay for diagnosis of MDR-TB. A questionnaire was used to collect demographic information from patients. The odds of having MDR-TB among patients who were cigarette smokers were four-times compared to non-smoking patients (aOR=3.94; 95%CI: 1.845-8.428, p<0.001). Alcohol abuse increased the chances of having MDR-TB by ten times (aOR=9.98: 95%CI; 2.414-41.267, p=0.001). Being HIV positive strongly increased the likelihood of having MDR-TB (aOR=2266.0: 95% CI; 407.5-2599.8, p<0.001). Compared to treatment failure, relapse and non-adherence were found to be strong predictors for MDR-TB (aOR=64.22: (95% CI; 12.786-322.507) p=0.001), and (aOR=37.44: (95% CI; 3.895-359.836, p=0.002), respectively. HIV infection, TB relapse, history of irregular treatment, cigarette smoking, alcohol abuse, and treatment failure (return) is factors development of MDR-TB. Integrated TB/HIV control programs that will include the establishment of strong diagnostic and drug delivery systems, patient management, and TB resistance surveillance systems are recommended.

Item Type: Article
Subjects: Eurolib Press > Medical Science
Depositing User: Managing Editor
Date Deposited: 30 Dec 2022 10:12
Last Modified: 23 Apr 2024 12:32
URI: http://info.submit4journal.com/id/eprint/546

Actions (login required)

View Item
View Item